FDA ques­tions hy­po­glycemia risk for No­vo Nordisk's once-week­ly in­sulin ahead of ad­comm

The FDA is rais­ing con­cerns about in­creased rates of hy­po­glycemia fol­low­ing treat­ment with No­vo Nordisk’s ex­per­i­men­tal once-week­ly basal in­sulin ahead of an ad­vi­so­ry com­mit­tee meet­ing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER